Amarna Therapeutics has signed a strategic collaboration with Swedish CDMO NorthX Biologics, representing the first step in advancing clinical trial manufacturing of Amarna’s gene therapy, Nimvec AM510.
The collab will start with the transfer of Amarna’s research-scale production process for Nimvec AM510 to NorthX, initiating the CMC development process at NorthX. The partners will focus on optimizing and scaling production processes, laying the groundwork for CGMP-compliant manufacturing to support first-in-human clinical trials.
Preclinical data with Nimvec AM510 has showcased its protective effects in delaying the onset of hyperglycemia and preventing the development of T1 diabetes in relevant animal models. Amarna hopes that AM510 can restore the immune tolerance to insulin and potentially cure diabetes patients.
The development of AM510 is based on Amarna's proprietary Nimvec platform, which has demonstrated promise in preclinical studies. Nimvec does not trigger strong immune responses, which means repeat dosing and better efficacy is possible. The platform moderates the immune system to induce tolerance, making it an ideal vehicle for Amarna's therapeutic approach.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!